Interface Biologics was founded by Dr. Paul Santerre, and is based on his groundbreaking work at the University of Toronto on improving the biocompatibility of medical implants. Dr. Santerre investigated the effects of low molecular weight additives in polyurethanes and their ability to migrate to the nano surface of materials, creating a non-reactive surface layer. In the process, he also discovered that the surface chemistry of certain materials could be engineered to respond to signals from the body’s own immune system. Dr. Santerre recognized the medical and commercial impact of his discoveries.
In December 2001, New Generation Biotech Fund provided the initial seed capital, and Interface Biologics was formed. The company has raised a total of $26MM in venture capital, most recently raising $1MM from MaRS Investment Accelerator Fund in 2011. IBI’s current investors are the Business Development Bank of Canada, Covington Capital and the MaRS Investment Accelerator Fund.
In July 2005, Interface Biologics moved into Toronto’s acclaimed MaRS Innovation Centre—a collaborative facility dedicated to accelerating emerging technologies, located near the University of Toronto campus and seven specialty hospitals. Interface Biologics boasts state of the art laboratory facilities and currently employs 20 people with dedicated expertise in biochemistry, pharmacology, engineering, chemistry, microbiology, biology, process manufacturing, marketing, finance and management.
Since its time at MaRS the company has been issued four U.S. Patents with a number of international jurisdictions and has filed twelve patent applications. The company received ISO 13485 certification in 2010 and manufactures its anti-thrombic additives in an ISO 9001 certified facility.
Interface Biologics, Inc.
MaRS Centre, South Tower
101 College Street, Suite 300
Main Line (416) 673-8170 Fax (416) 977-1329